3 March 2026 - AstraZeneca Korea said Tuesday that Imfinzi (durvalumab) is now covered by national health insurance as of Sunday for the first-line treatment of unresectable locally advanced or metastatic biliary tract cancer and advanced hepatocellular carcinoma (HCC) that is inoperable or not amenable to local therapy.

Imfinzi has been approved for health insurance coverage as a first-line treatment in combination with gemcitabine and cisplatin for patients with unresectable locally advanced or metastatic bile duct cancer. Imfinzi is administered at a dose of 1,500 mg in combination with chemotherapy every three weeks, followed by 1,500 mg monotherapy every four weeks in patients with biliary tract cancer.

Results from the longest follow-up period (median 41.3 months) in the global phase 3 TOPAZ-1 clinical trial in patients with advanced biliary tract cancer showed that the three-year overall survival rate for the Imfinzi–gemcitabine/cisplatin combination therapy was 14.6 percent (95 percent CI, 11.0–18.6), more than doubling the 6.9 percent (95 percent CI, 4.5–10.0) observed in the chemotherapy-only group.

Additionally, Imfinzi has been approved for health insurance coverage as a first-line treatment in combination with Imjudo (tremelimumab) (STRIDE regimen) for patients with unresectable or locally advanced HCC who are not candidates for surgery or local therapy. For HCC patients, Imfinzi 1,500 mg is administered in combination with Imjudo 300 mg on Day 1 of Cycle 1, followed by Imfinzi 1,500 mg monotherapy every four weeks.

Read Korea Biomedical Review article